6OOB
Human CYP3A4 bound to a suicide substrate
Summary for 6OOB
| Entry DOI | 10.2210/pdb6oob/pdb |
| Descriptor | Cytochrome P450 3A4, PROTOPORPHYRIN IX CONTAINING FE, 4-{[(2Z,6S)-6,7-dihydroxy-3,7-dimethyloct-2-en-1-yl]oxy}-7H-furo[3,2-g][1]benzopyran-7-one, ... (4 entities in total) |
| Functional Keywords | substrate, complex, oxidoreductase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 56746.71 |
| Authors | Sevrioukova, I.F. (deposition date: 2019-04-22, release date: 2019-09-11, Last modification date: 2023-10-11) |
| Primary citation | Sevrioukova, I.F. Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6',7'-Dihydroxybergamottin. Int J Mol Sci, 20:-, 2019 Cited by PubMed Abstract: Human cytochrome P450 3A4 (CYP3A4) is the most important drug-metabolizing enzyme. Some drugs and natural compounds can act as suicide (mechanism-based) inactivators of CYP3A4, leading to unanticipated drug-drug interactions, toxicity and therapeutic failures. Despite significant clinical and toxicological implications, the mechanism-based inactivation remains incompletely understood. This study provides the first direct insights into the interaction of CYP3A4 with three suicide substrates: mibefradil, an antihypertensive drug quickly withdrawn from the market; a semi-synthetic antibiotic azamulin; and a natural furanocoumarin, 6',7'-dihydroxybergamottin. Novel structural findings help better understand the suicide substrate binding and inhibitory mechanism, and can be used to improve the predictability of the binding ability, metabolic sites and inhibitory/inactivation potential of newly developed drugs and other chemicals relevant to public health. PubMed: 31480231DOI: 10.3390/ijms20174245 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.202 Å) |
Structure validation
Download full validation report
